NeuroOne Medical Technologies Corporation (NMTC)

In the past six months, NMTC's stock price has fluctuated, with an initial decline from $0.92 to $0.85 per share, and further to $0.66. The stock traded around $0.73 per share in November 2025, triggering a Nasdaq minimum bid price compliance extension until May 2026. However, positive developments include a 105% year-over-year revenue jump in Q3 fiscal year 2025, and a 163% increase in product revenue for the full fiscal year 2025. Q4 fiscal 2025 saw product revenue increase by 907%. NeuroOne received FDA clearance for its OneRF® Trigeminal Nerve Ablation System, with successful initial treatments. An expanded distribution deal with Zimmer Biomet, including exclusive rights for the OneRF Ablation System, brought a $3 million upfront payment. In April 2025, the company completed an oversubscribed capital raise of $8.2 million, fully funding operations through at least fiscal year 2026.

Specific details regarding demand seasonality for NeuroOne Medical Technologies Corp.'s products and services are not explicitly detailed in the provided search results.

NeuroOne Medical Technologies Corp. is a medical technology company focused on developing and commercializing minimally invasive and high-definition/high-precision electrode technology for various neurological conditions. The company operates within the Healthcare sector, specifically in the Healthcare Equipment and Supplies or Therapeutic Devices industry. NeuroOne's product portfolio includes the Evo® Cortical Electrodes and Evo® sEEG Electrodes for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording. Additionally, the company offers the OneRF® Ablation System for brain-related conditions and the OneRF® Trigeminal Nerve Ablation System for treating facial pain. NeuroOne also provides solutions for spinal cord stimulation, brain stimulation, and drug delivery for patients suffering from conditions such as epilepsy, trigeminal neuralgia, Parkinson's disease, dystonia, essential tremors, and chronic pain.

NeuroOne Medical Technologies Corp. is headquartered in Eden Prairie, Minnesota, United States. The company primarily provides its solutions in the United States.

NeuroOne Medical Technologies has maintained a positive media sentiment in the past year. The company has a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.75. Analysts have a consensus price target of $2.23, representing about 150.0% upside from its current price. Positive events include the FDA clearance for the OneRF® Trigeminal Nerve Ablation System and strong financial results, such as the 105% year-over-year revenue jump in Q3 fiscal 2025 and 907% product revenue growth in Q4 fiscal 2025. The expanded strategic partnership with Zimmer Biomet has also been a key driver.

NeuroOne Medical Technologies Corp. has a mixed ownership structure, with retail investors holding approximately 61.14% to 66.63% of the stock. Institutional investors hold between 21.62% and 33.63% of the shares, and insiders own about 4.79% to 11.42% of the company. Major institutional shareholders include Bleichroeder LP, Sio Capital Management LLC, Bard Associates Inc, Vanguard Group Inc, Perkins Capital Management Inc, AWM Investment Company, Inc., Renaissance Technologies Llc, and Geode Capital Management, Llc. David A. Rosa is the largest individual shareholder, owning 1.15 million shares, representing 2.29% of the company.